MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:21:36 ON 04 MAR 2007

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 18:21:58 ON 04 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3
DICTIONARY FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10801141.str

SAEED





chain nodes :
7 10
ring nodes :
1 2 3 4 5 6
ring/chain nodes :
8 9
chain bonds :
2-8 5-7 8-9 9-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
2-8 8-9 9-10
exact bonds :
5-7
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS

L1 STRUCTURE UPLOADED

=> D
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

SAEED

```
=> S L1
SAMPLE SEARCH INITIATED 18:22:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     3044 TO ITERATE

 65.7% PROCESSED     2000 ITERATIONS                                 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        57571 TO    64189
PROJECTED ANSWERS:           12386 TO    15556

L2            50 SEA SSS SAM L1

=> S L1 FULL
FULL SEARCH INITIATED 18:23:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    62237 TO ITERATE

100.0% PROCESSED    62237 ITERATIONS                             15206 ANSWERS
SEARCH TIME: 00.00.01

L3         15206 SEA SSS FUL L1

=> FILE CAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   173.00     173.21

FILE 'CAPLUS' ENTERED AT 18:23:57 ON 04 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 4 Mar 2007  VOL 146 ISS 11
FILE LAST UPDATED: 2 Mar 2007  (20070302/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> S L3
L4         3879 L3

=> FILE REG
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
```

	ENTRY	SESSION
FULL ESTIMATED COST	2.35	175.56

FILE 'REGISTRY' ENTERED AT 18:26:52 ON 04 MAR 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3
DICTIONARY FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\108011411.str



chain nodes :
7 10 14
ring nodes :
1 2 3 4 5 6 8 9 12 13
chain bonds :
2-8 5-7 9-10 12-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-12 12-13
exact/norm bonds :
2-8 8-9 8-13 9-10 9-12 12-13 12-14
exact bonds :
5-7

SAEED

normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 : 8 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
12:Atom 13:Atom 14:CLASS

L5 STRUCTURE UPLOADED

=> D
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L5
SAMPLE SEARCH INITIATED 18:27:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE

100.0% PROCESSED 2 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2 TO 124
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

=> S L5 FULL
FULL SEARCH INITIATED 18:27:18 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 55 TO ITERATE

100.0% PROCESSED 55 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.01

L7 13 SEA SSS FUL L5

=> FILE CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	347.66

FILE 'CAPLUS' ENTERED AT 18:27:23 ON 04 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Mar 2007 VOL 146 ISS 11
FILE LAST UPDATED: 2 Mar 2007 (20070302/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> S L7
L8 5 L7

=> D IBIB ABS HITSTR TOT

L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:844227 CAPLUS
DOCUMENT NUMBER: 145:438580
TITLE: Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity
AUTHOR(S): DiMauro, Erin F.; Newcomb, John; Nunes, Joseph J.; Bemis, Jean E.; Boucher, Christina; Buchanan, John L.; Buckner, William H.; Cee, Victor J.; Chai, Lilly; Deak, Holly L.; Epstein, Linda F.; Faust, Ted; Gallant, Paul; Geuns-Meyer, Stephanie D.; Gore, Anu; Gu, Yan; Henkle, Brad; Hodous, Brian L.; Hsieh, Faye; Huang, Xin; Kim, Joseph L.; Lee, Josie H.; Martin, Matthew W.; Masse, Craig E.; McGowan, David C.; Metz, Daniela; Mohn, Deanne; Morgenstern, Kurt A.; Oliveira-dos-Santos, Antonio; Patel, Vinod F.; Powers, David; Rose, Paul E.; Schneider, Stephen; Tomlinson, Susan A.; Tudor, Yan-Yan; Turci, Susan M.; Welcher, Andrew A.; White, Ryan D.; Zhao, Huilin; Zhu, Li; Zhu, Xiaotian
CORPORATE SOURCE: Department of Medicinal Chemistry, Department of HTS and Molecular Pharmacology and Department of Molecular Structure, Cambridge, MA, 02139, USA
SOURCE: Journal of Medicinal Chemistry (2006), 49(19), 5671-5686
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells. Genetic evidence in both mice and humans demonstrates that Lck kinase activity is critical for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation. Selective inhibition of Lck is expected to offer a new therapy for the treatment of T-cell-mediated autoimmune and inflammatory disease. Screening of our

L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

kinase-preferred collection identified aminoquinazoline I as a potent, nonselective inhibitor of Lck and T cell proliferation. In this report, we describe the synthesis and structure-activity relationships of a series of novel aminoquinazolines possessing in vitro mechanism-based potency. Two optimized, orally bioavailable compds. exhibit antiinflammatory activity (ED50 of 22 and 11 mg/kg, resp.) in the anti-CD3-induced prodn. of interleukin-2 (IL-2) in mice.

IT 882676-01-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of aminoquinazolines as potent and orally bioavailable inhibitors of lymphocyte-specific kinase)

RN 882676-01-9 CAPLUS
CN Benzamide, N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-4-methyl-3-[2-(methylamino)-6-quinazolinyl]- (9CI) (CA INDEX NAME)



IT 861881-17-6P 913067-87-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminoquinazolines as potent and orally bioavailable inhibitors of lymphocyte-specific kinase)

RN 861881-17-6 CAPLUS
CN 2-Azetidinone, 1-[2-amino-4-(trifluoromethyl)phenyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 913067-87-5 CAPLUS
CN Benzamide, N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (9CI) (CA INDEX NAME)

L8 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:381241 CAPLUS
DOCUMENT NUMBER: 144:432828
TITLE: Heteroaryl-substituted alkyne compounds as protein kinase inhibitors, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Chaffee, Stuart C.; Albrecht, Brian K.; Hodous, Brian L.; Martin, Matthew W.; McGowan, David C.; Dimauro, Erin F.; Reddy, Gade; Cee, Victor J.; Olivieri, Philip R.; Reed, Anthony; Romero, Karina
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 330 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044823	A2	20060427	WO 2005-US37299	20051017
WO 2006044823	A3	20060615		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006217380	A1	20060928	US 2005-251490	20051014
PRIORITY APPLN. INFO.:			US 2004-620100P P	20041018
			US 2005-251490 A	20051014

OTHER SOURCE(S): MARPAT 144:432828
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to heteroaryl-substituted alkynes of formula I, which are protein kinase modulators. In compds. I, W, X, Y, and Z are independently selected from N and (un)substituted C; R1 is (un)substituted amino, acyl, acyloxy, carboxylate, carbamoyl, thiocarbamoyl, etc.; and R2 is 5- to 8-membered monocyclic, 6- to 12-membered bicyclic, or 7- to 14-membered tricyclic ring system, optionally including 1-3 heteroatoms selected from O, N, and S; including stereoisomers, tautomers, solvates, salts, derivs., and prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I and a pharmaceutically acceptable carrier, as well as to the use of the compns. for the prophylaxis and treatment of protein kinase-mediated diseases,

L8 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
including inflammation, cancer and related conditions. Chlorination of 3-iodo-4-methylbenzoic acid and amidation with 3-trifluoromethylaniline gave benzamide II, which underwent coupling with 2-amino-5-ethynylpyrimidine (prepn. from 2-amino-5-iodopyrimidine and trimethylsilylacetylene is given) to give pyrimidinylalkyne III. Several compds. of the invention, e.g., III, express IC50 values of less than or equal to 10 μM both for Tie-2 and Lck kinase.

IT 884604-15-3P, 5-[(2-Amino-5-pyrimidinyl)ethynyl]-N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-2-(methyloxy)benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heteroaryl-substituted alkynes as protein kinase modulators)

RN 884604-15-3 CAPLUS

CN Benzamide, 5-[(2-amino-5-pyrimidinyl)ethynyl]-N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:343955 CAPLUS

DOCUMENT NUMBER: 144:390936

TITLE: Aryl nitrogen-containing bicyclic compounds and their preparation, pharmaceutical compositions, and protein kinase inhibitory activity and use in prophylaxis and treatment of kinase-mediated diseases

INVENTOR(S): Patel, Vinod F.; Kim, Joseph L.; Geuns-Meyer, Stephanie D.; Chaffee, Stuart C.; Cee, Victor J.; Hodous, Brian L.; Bellon, Steven; Harmange, Jean-Christophe; Olivieri, Philip R.; Thaman, Maya C.; Dimauro, Erin F.; Buchanan, John L.; Mcgowan, David C.; Albrecht, Brian K.; Deak, Holly L.; Bemis, Jean E.; White, Ryan; Martin, Matthew W.; Habgood, Gregory J.; Tempest, Paul A.; Masse, Craig E.; Buckner, William H.; Herberich, Bradley J.; Graceffa, Russell; Zhang, Dawei; Xu, Shimin; Sham, Kelvin; Rzasa, Robert M.; Falsey, James Richard; Chakrabarti, Partha P.; Cao, Guo-Qiang; Tomlinson, Susan Ann; Pettus, Liping H.; Smith, Adrian Leonard; Paras, Nick A.; Liu, Gang; Demorin, Frenel F.; Tasker, Andrew; Reed, Anthony

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: PCT Int. Appl., 876 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006039718	A2	20060413	WO 2005-US35873	20051003
WO 2006039718	A3	20060713		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:	US 2004-615535P	P	20041001
	US 2005-240590	A	20050930

OTHER SOURCE(S): MARPAT 144:390936

GI

L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

II

AB The invention comprises a class of compds. of formula I useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. Compds. of formula I wherein A1 and one of A2 and A3 are independently CR5 or N; B is a bond, CR5R6, CO, NR6, O, S, SO, or SO2; R1 is halo, haloalkyl, NO2, CN, H, NH2 and derivs., OH and derivs., SH and derivs., CHO and derivs., OC(O)R and derivs., CO2H and derivs., CONH2 and derivs., CSNH2 and derivs., NHCHO and derivs., NHC(S)H and derivs., NHCONH2 and derivs., NHCSNH2 and derivs., SO2H and derivs., SO2NH2 and derivs., etc.; R2, R4, and R5 are independently H, halo, haloalkyl, NO2, CN, OH and derivs., SH and derivs., NH2 and derivs., CHO and derivs., CO2H and derivs., CONH2 and derivs., NHCONH2 and derivs., SO2H and derivs., SO2NH2 and derivs., NHSO2H and derivs., (un)substituted C1-10 (hetero)alkyl, (un)substituted C2-10 alkenyl, (un)substituted C2-10 (hetero)alkynyl, (un)substituted 3- to 10-membered (hetero)cycloalkyl, (un)substituted 4- to 10-membered (hetero)cycloalkenyl, etc.; R3 is (un)substituted (un)saturated 5- to 8-membered (hetero)monocyclic, (un)substituted (un)saturated 6- to 12-membered (hetero)bicyclic, or (un)substituted (un)saturated 7- to 14-membered (hetero)tricyclic rings; R6 is H, (un)substituted C1-10 (hetero)alkyl, (un)substituted C2-10 (hetero)alkenyl, (un)substituted C2-10 (hetero)alkynyl, (un)substituted 3- to 10-membered (hetero)cycloalkyl, (un)substituted 4- to 10-membered (hetero)cycloalkenyl; and their stereoisomers, tautomers, solvates, pharmaceutically acceptable salts, derivs., and prodrugs thereof are claimed. Accordingly, the invention also comprises pharmaceutical compns. comprising the compds. of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compds. and compns. of the invention, and intermediates and processes useful for the preparation of compds. of the invention. Example compound II was prepared by boration of 3-iodo-4-methylbenzoic acid with bis(pinacolato)diboron; the resulting 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid was converted to the corresponding acid chloride, in situ, and reacted with 2-fluoro-5-trifluoromethylbenzeneamine to give N-(2-fluoro-5-fluoromethylphenyl)-4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide, which underwent cross-coupling with 6-bromo-N-methylquinazolin-2-amine to give compd. II. About 2000 invention compds. of formula I were prepd. by similar procedures. All the invention compds. were tested for their protein kinase inhibitory activity. Example compd. I along with many other invention compd. showed good inhibitory activity. From the HTRF assay, the IC50 values for inhibition of Tie-2 was detd. to be less than or equal to 1 μM for some of the invention compds. For the inhibition of Lck kinase enzyme, the some of the exemplary compds. exhibited an av. IC50 value of 25 μM or less and some invention compd. exhibited an IC50 value of 1 μM or less, in the human HTRF assay. The invention compds. were also found to be active inhibitors or the VEGF kinase receptor. Furthermore, some of the invention compds. exhibited activities in the monocyte assay with IC50 values of 25 μM or less. Various compds. of the invention have selective inhibitory activity for specific kinase receptor enzymes, including Tie-2, Lck, p38 and VEGFR/KDR. Accordingly, the compds. of the invention would be useful in therapy as antineoplasia agents, antiinflammatory agents, or to minimize deleterious effects of Tie-2, Lck, VEGF and/or p38.

IT 861881-17-6P 882676-01-9P 882676-02-0P
882676-14-4P 882676-15-5P 882676-16-6P
882678-66-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aryl nitrogen-containing bicyclic compds. and their protein kinase inhibitory activity and use in prophylaxis and treatment of kinase-mediated diseases)

RN 861881-17-6 CAPLUS

CN 2-Azetidinone, 1-[2-amino-4-(trifluoromethyl)phenyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)



RN 882676-01-9 CAPLUS

CN Benzamide, N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-4-methyl-3-[2-(methylamino)-6-quinazolinyl]- (9CI) (CA INDEX NAME)

L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 882676-02-0 CAPLUS
CN Benzamide, N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-4-methyl-3-[2-[[2-(1-piperidinyl)ethyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 882676-14-4 CAPLUS
CN Benzamide, N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-4-methyl-3-[2-[[3-(4-morpholinyl)propyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 882676-15-5 CAPLUS
CN Benzamide, 3-[2-[[3-(diethylamino)propyl]amino]-6-quinazolinyl]-N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-4-methyl- (9CI)

L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(Reactant or reagent)
(intermediate; prepn. of aryl nitrogen-contg. bicyclic compds. and their protein kinase inhibitory activity and use in prophylaxis and treatment of kinase-mediated diseases)

RN 861881-16-5 CAPLUS
CN 2-Azetidinone, 3,3-dimethyl-1-[2-nitro-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(CA INDEX NAME)



RN 882676-16-6 CAPLUS
CN Benzamide, N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-4-methyl-3-[2-[[3-(1-piperidinyl)propyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 882678-66-2 CAPLUS
CN Benzamide, 5-(2-amino-6-quinazolinyl)-N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



IT 861881-16-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:696877 CAPLUS
DOCUMENT NUMBER: 143:211847
TITLE: Preparation of heteroaryl substituted naphthalenes as inhibitors of Lck, VEGFR and/or HGF related activity
INVENTOR(S): Potashman, Michele; Kim, Tae-Seong; Bellon, Steven; Booker, Shon; Cheng, Yuan; Kim, Joseph L.; Tasker, Andrew; Xi, Ning; Xu, Shimin; Harmange, Jean-Christophe; Borg, George; Weiss, Matthew; Hodous, Brian L.; Graceffa, Russell; Buckner, Willian H.; Masse, Craig E.; Choquette, Deborah; Martin, Matthew W.; Germain, Julie; Dipietro, Lucian V.; Chaffee, Stuart C.; Nunes, Joseph J.; Buchanan, John L.; Habgood, Gregory J.; McGowan, David C.; Whittington, Douglas A.
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 444 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070891	A2	20050804	WO 2005-US2326	20050124
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005206571	A1	20050804	AU 2005-206571	20050124
CA 2553423	A1	20050804	CA 2005-2553423	20050124
EP 1713484	A2	20061025	EP 2005-722533	20050124
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
US 2006241115	A1	20061026	US 2005-42634	20050124
NO 2006003693	A	20061023	NO 2006-3693	20060817
PRIORITY APPLN. INFO.:			US 2004-538691P	P 20040123
			WO 2005-US2326	W 20050124

OTHER SOURCE(S): MARPAT 143:211847
GI

L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



II

AB The title compds. I [R1XAYR; R = (un)substituted aryl, heterocyclyl, cycloalkyl, etc.; R1 = (un)substituted quinolinyl, quinazolinyl, pyrimidinyl, etc.; A = (un)substituted naphthalenediyl, etc.; X = O, S, (un)substituted NH, CH2; Y = NHCO, CONH, etc.] which are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases, were prepared E.g., a multi-step synthesis of II, starting from 6-hydroxy-2-naphthoic acid, was given. The compds. I showed inhibition of LcK kinase, c-Met kinase, and VEGFR kinase at less than 10 μM. The invention encompasses novel compds. I, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutically compns. and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like.

IT 861875-02-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl substituted naphthalenes as inhibitors of Lck, VEGFR and/or HGF related activity)

RN 861875-02-7 CAPLUS

CN 1-Naphthalenecarboxamide, N-[2-(3,3-dimethyl-2-oxo-1-azetidinyl)-5-(trifluoromethyl)phenyl]-6-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 861881-16-5P 861881-17-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heteroaryl substituted naphthalenes as inhibitors of Lck, VEGFR and/or HGF related activity)

RN 861881-16-5 CAPLUS

CN 2-Azetidinone, 3,3-dimethyl-1-[2-nitro-4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 861881-17-6 CAPLUS

CN 2-Azetidinone, 1-[2-amino-4-(trifluoromethyl)phenyl]-3,3-dimethyl- (9CI) (CA INDEX NAME)

L8 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L8 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:799552 CAPLUS
DOCUMENT NUMBER: 141:314019
TITLE: Processes for production of (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide derivatives via stereoselective reduction of N-[4-(trifluoromethyl)phenyl]-3-oxopentanamide
INVENTOR(S): Tanaka, Tatsuyoshi; Sugawara, Masanobu; Maeda, Hirofumi; Nishiyama, Akira; Yasohara, Yoshihiko; Nagashima, Nobuo
PATENT ASSIGNEE(S): Kaneka Corporation, Japan
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083166	A1	20040930	WO 2004-JP3535	20040317
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004199005	A1	20041007	US 2004-801141	20040316
CA 2515789	A1	20040930	CA 2004-2515789	20040317
EP 1604975	A1	20051214	EP 2004-721366	20040317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004007954	A	20060307	BR 2004-7954	20040317

PRIORITY APPLN. INFO.:

JP 2003-72358	A	20030317
JP 2003-98452	A	20030401
US 2003-462687P	P	20030415
WO 2004-JP3535	W	20040317

OTHER SOURCE(S): MARPAT 141:314019
GI

L8 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



III



II



IV

AB The invention provides processes by which (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide derivs. (I; R4 = C1-12 alkyl, C6-12 aryl, C7-12 aralkyl) useful as intermediates of drugs, particularly, cholesteryl ester transfer protein (CETP) inhibitor can be easily and simply produced from easily available starting materials. According to the invention, (S)-N-[4-(trifluoromethyl)phenyl]-3-hydroxypentanamide (II) is produced from easily available raw materials and converted into (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide (III) through (R)-4-ethyl-1-[4-(trifluoromethyl)phenyl]-2-azetidinone (IV). Further, (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide derivs. I are produced by reacting (R)-4-ethyl-1-[4-(trifluoromethyl)phenyl]-2-azetidinone with a carbamic acid ester. Thus, 12.83 g 4-(trifluoromethyl)aniline was added dropwise to 10.0 g neat Me 3-oxopentanoate at 115°, stirred for 25 min, treated with 50 mL toluene, and heated under stirring for 12 h to give 11.22 g N-[4-(trifluoromethyl)phenyl]-3-oxopentanamide (57%) which (1.30 g) was hydrogenated in the presence of 50.0 mg ((S)-BINAP)RuBr2 in 20 mL MeOH/H2O (10/1) at 60° and hydrogen pressure of 3.0 kg/cm2 to give 1.23 g II (95%, 84.7% ee). Methanesulfonyl chloride (703 mg) was added dropwise to a solution of 1.07 g II and 621 mg Et3N in 8 mL Et3N at 0° over 10 min and stirred at the same temperature for 1 h to give 1.48 g crude (S)-N-[4-(trifluoromethyl)phenyl]-3-[(methanesulfonyl)oxy]pentanamide (V) (97%). A solution of 1.346 g V in 2.7 mL CH2Cl2 and 10.8 mL DMF was added dropwise to a suspension of 158.7 mg NaH in the same solvent mixture at room temperature over 15 min and stirred at room temperature for 1 h to give 996.3 mg crude IV (87% yield, 83.0% ee) which was purified by silica gel chromatog. (864 mg) and recrystd. from hexane to give 454.3 mg IV (47%, 100% ee). IV (420 mg) was dissolved in 7.0 mL MeOH at room temp., treated with 28 wt.% NaOMe/MeOH (668 mg), and stirred at room temp. for 1 h to give 459 mg I (R4 = Me) (97%, 100% ee).

IT 765315-38-6P, (R)-3-Ethyl-1-[4-(trifluoromethyl)phenyl]azetidin-2-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide derivs. via stereoselective reduction of N-[4-(trifluoromethyl)phenyl]-3-oxopentanamide)

RN 765315-38-6 CAPLUS

CN 2-Azetidinone, 3-ethyl-1-[4-(trifluoromethyl)phenyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FILE CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.58	378.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.90	-3.90

FILE 'CAPLUS' ENTERED AT 18:32:36 ON 04 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Mar 2007 VOL 146 ISS 11
FILE LAST UPDATED: 2 Mar 2007 (20070302/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> D

L8 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:844227 CAPLUS
DN 145:438580
TI Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity
AU DiMauro, Erin F.; Newcomb, John; Nunes, Joseph J.; Bemis, Jean E.; Boucher, Christina; Buchanan, John L.; Buckner, William H.; Cee, Victor J.; Chai, Lilly; Deak, Holly L.; Epstein, Linda F.; Faust, Ted; Gallant, Paul; Geuns-Meyer, Stephanie D.; Gore, Anu; Gu, Yan; Henkle, Brad; Hodous, Brian L.; Hsieh, Faye; Huang, Xin; Kim, Joseph L.; Lee, Josie H.; Martin, Matthew W.; Masse, Craig E.; McGowan, David C.; Metz, Daniela; Mohn, Deanna; Morgenstern, Kurt A.; Oliveira-dos-Santos, Antonio; Patel, Vinod F.; Powers, David; Rose, Paul E.; Schneider, Stephen; Tomlinson, Susan A.; Tudor, Yan-Yan; Turci, Susan M.; Welcher, Andrew A.; White, Ryan D.; Zhao, Huilin; Zhu, Li; Zhu, Xiaotian
CS Department of Medicinal Chemistry, Department of HTS and Molecular Pharmacology and Department of Molecular Structure, Cambridge, MA, 02139, USA
SO Journal of Medicinal Chemistry (2006), 49(19), 5671-5686
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
RE.CNT 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.65	379.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.90

FILE 'REGISTRY' ENTERED AT 18:33:28 ON 04 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3
DICTIONARY FILE UPDATES: 2 MAR 2007 HIGHEST RN 924584-96-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\108011412.str



```
chain nodes :
7  10  12  13  14  15
ring nodes :
1  2  3  4  5  6
ring/chain nodes :
8  9
chain bonds :
2-8  5-7  8-9  9-10  9-12  12-13  13-14  13-15
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6
exact/norm bonds :
2-8  8-9  9-10  13-14  13-15
exact bonds :
5-7  9-12  12-13
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 : 8 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 12:CLASS  13:CLASS  14:CLASS  15:CLASS



L9      STRUCTURE UPLOADED

=> D
L9 HAS NO ANSWERS
L9              STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> S L9
SAMPLE SEARCH INITIATED 18:33:49 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       73 TO ITERATE

100.0% PROCESSED       73 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          948 TO     1972
PROJECTED ANSWERS:               0 TO        0

L10           0 SEA SSS SAM L9

=> S L9 FULL
FULL SEARCH INITIATED 18:33:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1706 TO ITERATE

100.0% PROCESSED     1706 ITERATIONS                              4 ANSWERS
SEARCH TIME: 00.00.01

L11           4 SEA SSS FUL L9

=> FILE CAPLUS
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
```

SAEED

FULL ESTIMATED COST 172.10 551.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.90

FILE 'CAPLUS' ENTERED AT 18:34:10 ON 04 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Mar 2007 VOL 146 ISS 11
FILE LAST UPDATED: 2 Mar 2007 (20070302/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> S L11
L12 1 L11

=> D IBIB ABS HITSTR TOT

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:799552 CAPLUS
DOCUMENT NUMBER: 141:314019
TITLE: Processes for production of (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide derivatives via stereoselective reduction of N-[4-(trifluoromethyl)phenyl]-3-oxopentanamide
INVENTOR(S): Tanaka, Tatsuyoshi; Sugawara, Masanobu; Maeda, Hirofumi; Nishiyama, Akira; Yasohara, Yoshihiko; Nagashima, Nobuo
PATENT ASSIGNEE(S): Kaneka Corporation, Japan
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004083166	A1	20040930	WO 2004-JP3535	20040317
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004199005	A1	20041007	US 2004-801141	20040316
CA 2515789	A1	20040930	CA 2004-2515789	20040317
EP 1604975	A1	20051214	EP 2004-721366	20040317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
BR 2004007954	A	20060307	BR 2004-7954	20040317
PRIORITY APPLN. INFO.:			JP 2003-72358 A	20030317
			JP 2003-98452 A	20030401
			US 2003-462687P P	20030415
			WO 2004-JP3535 W	20040317

OTHER SOURCE(S): MARPAT 141:314019
GI

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


I


III


II


IV

AB The invention provides processes by which (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide derivs. (I; R4 = C1-12 alkyl, C6-12 aryl, C7-12 aralkyl) useful as intermediates of drugs, particularly, cholesteryl ester transfer protein (CETP) inhibitor can be easily and simply produced from easily available starting materials. According to the invention, (S)-N-[4-(trifluoromethyl)phenyl]-3-hydroxypentanamide (II) is produced from easily available raw materials and converted into (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide (III) through (R)-4-ethyl-1-[4-(trifluoromethyl)phenyl]-2-azetidinone (IV). Further, (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide derivs. I are produced by reacting (R)-4-ethyl-1-[4-(trifluoromethyl)phenyl]-2-azetidinone with a carbamic acid ester. Thus, 12.83 g 4-(trifluoromethyl)aniline was added dropwise to 10.0 g neat Me 3-oxopentanoate at 115°, stirred for 25 min, treated with 50 mL toluene, and heated under stirring for 12 h to give 11.22 g N-[4-(trifluoromethyl)phenyl]-3-oxopentanamide (57%) which (1.30 g) was hydrogenated in the presence of 50.0 mg ((S)-BINAP)RuBr2 in 20 mL MeOH/H2O (10/1) at 60° and hydrogen pressure of 3.0 kg/cm2 to give 1.23 g II (95%, 84.7% ee). Methanesulfonyl chloride (703 mg) was added dropwise to a solution of 1.07 g II and 621 mg Et3N in 8 mL Et3N at 0° over 10 min and stirred at the same temperature for 1 h to give 1.48 g crude (S)-N-[4-(trifluoromethyl)phenyl]-3-[(methanesulfonyl)oxy]pentanamide (V) (97%). A solution of 1.346 g V in 2.7 mL CH2Cl2 and 10.8 mL DMF was added dropwise to a suspension of 158.7 mg NaH in the same solvent mixture at room temperature over 15 min and stirred at room temperature for 1 h to give 996.3 mg crude IV (87% yield, 83.0% ee) which was purified by silica gel chromatog. (864 mg) and recrystd. from hexane to give 454.3 mg IV (47%,

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
100% ee). IV (420 mg) was dissolved in 7.0 mL MeOH at room temp., treated with 28 wt.% NaOMe/MeOH (668 mg), and stirred at room temp. for 1 h to give 459 mg I (R4 = Me) (97%, 100% ee).
IT 765315-35-3P, (S)-N-[4-(Trifluoromethyl)phenyl]-3-hydroxypentanamide 765315-36-4P, (S)-N-[4-(Trifluoromethyl)phenyl]-3-[(methanesulfonyl)oxy]pentanamide 765315-37-5P, (S)-N-[4-(Trifluoromethyl)phenyl]-3-[(4-methylphenylsulfonyl)oxy]pentanamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (R)-3-[4-(trifluoromethyl)phenylamino]pentanamide derivs. via stereoselective reduction of N-[4-(trifluoromethyl)phenyl]-3-oxopentanamide)
RN 765315-35-3 CAPLUS
CN Pentanamide, 3-hydroxy-N-[4-(trifluoromethyl)phenyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765315-36-4 CAPLUS
CN Pentanamide, 3-[(methylsulfonyl)oxy]-N-[4-(trifluoromethyl)phenyl]-, (3S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 765315-37-5 CAPLUS
CN Pentanamide, 3-[[(4-methylphenyl)sulfonyl]oxy]-N-[4-(trifluoromethyl)phenyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L12 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> LOGOFF
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:Y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     6.21     558.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -0.78      -4.68

STN INTERNATIONAL LOGOFF AT 18:35:17 ON 04 MAR 2007
```